ClinicalTrials.gg
Enrolling by invitationNCT00583817EVOLVE AortaUpdated Oct 22, 2026

Endovascular Treatment of Thoracic Aortic Disease

An interventional study of Endovascular stent-graft implantation in Thoracic Aortic Aneurysms, Dissecting, Aneurysm and Ascending Aorta Aneurysm, sponsored by Matthew Eagleton. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionAneurysm, Ascending AortaRegistry: Aortic Aneurysm, ThoracicReclassifiedWhy we changed it
Registry
Aortic Aneurysm, Thoracic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aneurysm, Ascending Aorta
Why
  1. The study's listed conditions name Aneurysm, Ascending Aorta, a narrower term within Aortic Aneurysm, Thoracic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Matthew Eagleton · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the role endovascular therapy to treat aortic disease involving the ascending aorta, the aortic arch, and the visceral segment of the aorta (or thoracoabdominal aorta)

Read the detailed description

This study is a prospective, non-randomized, single-site evaluation of the use of novel endovascular technology to treat complex aortic disease.

In an effort to allow for the evaluation of patients with both complex anatomic condition and challenging physiologic situations there are three study subsections as follows:

  1. Ascending Arm Protocol: The intended use of the study is to provide endovascular therapy to patients with ascending aortic pathology including aneurysm, pseudoaneurysm, and/or aortic dissection who are considered high risk for conventional surgery. This will involve disease in the aorta from the sinotubular junction to the innominate artery.
  2. Aortic Arch Arm Protocol: The intended use of the study is to provide endovascular therapy to patients with aortic arch pathology including aneurysm, pseudoaneurysm and/or aortic dissection who are considered high risk for conventional surgery. This will involve disease in aorta from the sinotubular junction to descending thoracic aorta.
  3. Thoracobabdominal Aortic Arm Protocol: The intended use of the study is to provide endovascular therapy to patients with thoracoabdominal aortic pathology including aortic aneurysms, renal aneurysms, and superior mesenteric artery aneurysms. This will involve the aorta from the left carotid artery origin through the iliac artery bifurcation.

In addition, the purpose of the study is also characterized based on the protocol arm that patients are enrolled:

  1. Ascending Arm Protocol: The purpose of this study is to assess the safety, efficacy, and intermediate (or long-term) rupture free survival rate of high risk surgical patients undergoing endovascular repair of ASCENDING AORTIC pathology including aortic dissection, aortic aneurysm, and/or aortic pseudoaneurysm. The objectives of this arm are as follows:

    • To assess the safety, efficacy and intermediate (or long-term) durability of an endovascular prosthesis as a means of preventing ascending aortic growth and rupture in high risk patients.
    • To measure the physiologic effects and outcomes of endovascular aneurysm repair.
    • Establish selection criteria, improve device design, operative technique and follow-up procedures for patients undergoing endovascular aneurysm repair.
  2. Arch Arm Protocol: The purpose of this study is to assess the safety, efficacy, and intermediate (or long-term) rupture free survival rate of high risk surgical patients undergoing endovascular repair of AORTIC ARCH pathology including aortic aneurysm, pseudoaneurysm and/or dissection. The objectives of this arm are as follows:

    • To assess the safety, efficacy and intermediate (or long-term) durability of an endovascular prosthesis as a means of preventing aortic arch growth and rupture in high risk patients.
    • To measure the physiologic effects and outcomes of endovascular aneurysm repair.
    • Establish selection criteria, improve device design, operative technique and follow-up procedures for patients undergoing endovascular aneurysm repair.
  3. Thoracoabdominal Arm Protocol: The purpose of this study is to assess the long-term safety, durability and rupture free survival of surgical patients undergoing endovascular repair of the THORACOABDOMINAL AORTA involving pathologies that include thoracoabdominal aortic aneurysms, renal artery aneurysms and superior mesenteric artery aneurysms.

    • To assess the long-term safety and durability of an endovascular prosthesis as a means of preventing aneurysm growth and rupture in patients having aneurysms involving the THORACOABDOMINAL AORTA.
    • To measure the physiologic effects and outcomes of endovascular aneurysm repair.
    • Establish selection criteria, improve device design, operative technique and follow-up procedures for patients undergoing endovascular aneurysm repair involving the THORACOABDOMINAL AORTA.
02

Conditions studied

  • Thoracic Aortic Aneurysms
  • Dissecting, Aneurysm
  • Ascending Aorta Aneurysm
  • Aortic Arch; Aneurysm, Dissecting
  • Ascending Aortic Dissection
  • Thoracoabdominal Aortic Aneurysm
  • Renal Artery Aneurysm
  • Superior Mesenteric Artery Aneurysm
  • Aortic Dissection
03

In context

Aneurysm, Ascending Aorta Reclassified

22 studies on the registry are indexed under Aneurysm, Ascending Aorta; 11 are open to participants now.

This study's planned enrollment of 170 is close to the median of 164 across 12 interventional studies indexed under Aneurysm, Ascending Aorta.

Browse Aneurysm, Ascending Aorta studies →

Lead sponsor

Matthew Eagleton is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Aneurysm, Ascending Aorta, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Aneurysm, Thoracic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Ascending Arm Protocol:

  1. General Inclusion Criteria (Must meet ALL of the following):

    • greater than 2 years
    • Suitable arterial anatomy
    • Absence of systemic disease or allergy that precludes an endovascular repair
    • Capable of giving and willingness to comply with follow up schedule
    • Patient is considered high or prohibitive risk for open surgical repair of the ascending aneurysm or dissection
  2. Anatomic Inclusion Criteria

    • Have ONE of the following

      1. Focal aneurysm in ascending aorta
      2. Pseudoaneurysms and/or dissections that are distal to the sinotubular junction.
      3. A thoracoabdominal aortic aneurysm ≥ 5.0 cm in women and ≥ 5.5 cm in men
      4. Have morphology or growth suggestive of immanent rupture
    • Must meet ALL of the following:

      1. Proximal Fixation:

        1. >15 mm aortic length distal to a patent coronary artery or coronary artery bypass that are considered patent and necessary for proper cardiac perfusion.

          • Proximal fixation may occur in either native aorta or surgical graft
          • In the setting of the aortic dissection, the proximal fixation must be proximal to the entry tear.
          • In the setting of aortic dissection, true lumen size must be large enough to allow deployment of the device
        2. Aortic diameter at the sinotubular junction >20 mm and ≤ 38mm
      2. Distal Fixation: a length of distal ascending aorta >5mm proximal to the innominate artery whereby seal and fixation can be achieved (the dissection flap may transcend the arch, but the seal must be achievable within the true lumen of the dissection)

        1. Aortic diameter (true lumen diameter in the setting of a dissection) at the innominate artery is ≤ 42mm. If the diameter at the innominate artery is ≥ 38mm the Low Profile version must be used
        2. Distance from the ascending aorta to the innominate artery must be >35mm
    • Iliac artery access

      1. Iliac anatomy must allow for the delivery of the endograft device which is loaded within an 18F-24F sheath.
      2. Conduits to the iliac vessels or aorta may be used if deemed necessary
      3. In the setting of an aortic dissection, access into the true lumen throughout the length of the aorta must be obtainable

Arch Arm Protocol

  1. General Inclusion Criteria (Must meet ALL of the following):

    • Life expectancy greater than 2 years
    • Suitable arterial anatomy
    • Absence of systemic disease or allergy that precludes an endovascular repair
    • Capable of giving informed consent and willingness to comply with follow up schedule
    • Patient is considered high or prohibitive risk for open surgical repair of the ascending aneurysm or dissection
  2. Anatomic Inclusion Criteria

    • Must meet ALL of the following:

      1. Aneurysm of the ascending aorta or aortic arch/proximal descending thoracic aorta that is >5.5cm or is considered to be at high risk for rupture or dissection given the morphologic characteristics of the aneurysm (or diverticulum).
      2. Proximal aortic fixation zone:

        1. Native aorta or surgical graft (If surgical graft in ascending aorta, the angulation within the graft must be \<90 degrees)
        2. Diameter: 20-42mm
        3. Proximal neck length ≥10mm
        4. Ascending aortic length >50mm
        5. Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion
      3. Distal aortic fixation zone:

        1. Native aorta or surgical graft
        2. Diameter: 20-42mm
        3. Distal neck length ≥10mm
      4. Supra-aortic trunk (brachiocephalic) vessels

        1. Although the prosthesis will typically have two branches, modifications to the design will allow for a single branch or three branches. Thus, it is generally planned that at least one extra-anatomic bypass graft will be done in conjunction (or in a staged fashion) with the procedure. The two vessels incorporated into the endograft repair would most commonly be the innominate artery and left carotid artery. However, the innominate artery may be coupled with the left subclavian artery in the setting of a bovine arch whereby the flow to the left carotid would come from a left subclavian to carotid bypass. Similarly, the left carotid and subclavian artery may be branched, or simply one vessel branched should specific anatomic limitations exist. In such a situation, multiple extra-anatomic bypasses may be necessary. Thus the inclusion criteria are defined for each artery, yet any combination of arteries may be used for a repair.
        2. Diameter of vessel(s) to be incorporated into endograft

          • Innominate artery: 8-22 mm.
          • Left (or right) common carotid artery: 6-16mm
          • Left (or right) subclavian artery: 5-20mm
          • Length of sealing zone ≥ 10mm
          • Acceptable tortuosity
      5. In the setting of an aortic dissection the following criteria must exist:

        1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel
        2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent graft would be anticipated to seal off the dissection lumen
        3. A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created
        4. A true lumen size large enough to deploy the device and still gain access into the target branches
      6. In the setting of a more distal disease, the repair may be coupled with a thoracoabdominal branched device, infrarenal device, and/or internal iliac branch device - typically performed in a staged fashion
      7. Iliac anatomy must allow for the delivery of the arch branch device which is loaded within an 18F-24F sheath. Conduits to the iliac vessels or aorta may be used if deemed necessary.

Thoracoabdominal Arm Protocol

  1. General Inclusion Criteria (Must meet ALL of the following):

    • Life expectancy greater than 2 years
    • Suitable arterial anatomy
    • Absence of systemic disease or allergy that precludes an endovascular repair
    • Capable of giving informed consent and willingness to comply with follow up schedule
  2. Anatomic Inclusion Criteria

    • Presence of at least one of the following aneurysms is necessary to drive the need for a repair with a fenestrated/branched device:

      1. A thoracoabdominal aortic aneurysm ≥ 5 cm in women and ≥ 5.5 cm in men or suggestive of a high risk of rupture as a result of morphology, growth history or symptoms
      2. A renal artery aneurysm > 20 mm (or twice the diameter of native renal artery)
      3. An SMA aneurysm >30 mm
    • Outside of the "Indications for Use" for commercially available fenestrated or branched endografts approved for use for the treatment of these aneurysms.
    • Proximal neck

      1. Diameter ≤ 40 mm, ≥20 mm
      2. Proximal neck length ≥ 10mm.
      3. The proximal landing zone may be in a prior endograft or a prior surgical graft.
    • Iliac Artery

      1. Diameter ≥ 7 mm (anticipated diameter following balloon angioplasty, stenting, dottoring, or conduit) or ≥ 6 mm for patients receiving an Low-Profile device.
      2. Iliac angulation that will not preclude device delivery or surgical modification of the iliac system
      3. For a bifurcated or aorto-monoiliac prosthesis, iliac implantation sites require ≤ 20 mm in diameter and ≥ 20 mm in length
    • For a straight aorto-aortic prosthesis, distal neck (normal aorta between the aneurysm and iliac bifurcation) ≥ 10 mm in length and ≤ 40 mm in diameter
    • If a hypogastric branch will be used to treat the common iliac aneurysm

      1. The intended common iliac artery is > 20mm in diameter or the aneurysm has morphology concerning for rupture; and
      2. The intended distal fixation site within the internal iliac is ≤ 10mm in diameter.
    • Renal arteries or other visceral vessels arising from the aorta in an orientation that is evident and measurable from cross-sectional imaging (CT or MR)
    • Visceral branch diameters (for incorporated vessels) between 4 mm - 11 mm at the intended distal sealing site (thus distal to a visceral artery aneurysm in such circumstances).
    • Greater than 5 mm of proximal visceral branch length to allow for a seal with the mated device, or the ability to exclude an early branch.
    • In the setting of an aortic dissection the following criteria must exist:

      1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel
      2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stentgraft would be anticipated to seal off the dissection lumen
      3. A sealing zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen, or surgically created
      4. A true lumen size large enough to deploy the device and still gain access into the target branches
    • In the setting of a more proximal disease, the repair may be coupled with an arch-branched device, thoracic aortic endograft, or surgical aortic repair - typically performed in a staged fashion

General Exclusion Criteria

  1. Patient can be treated in accordance with the instructions for use with a commercially marketed endovascular prosthesis
  2. Patient qualifies for treatment of thoracoabdominal aortic repair under an industry-sponsored clinical trial, open to enrollment at the Massachusetts General Hospital \& Brigham and Women's Hospital
  3. Pregnancy
  4. History of anaphylactic reaction to contrast material with an inability to properly prophylax the patient appropriately
  5. Known sensitivity or allergy to materials of construction of the device (including the materials of the LP device).
  6. Body habitus that would inhibit X-ray visualization of the aorta
  7. Subject had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned \<30 days from the endovascular repair
  8. Unstable angina
  9. Unwilling to comply with follow up schedule
  10. Systemic or local infection that may increase the risk of endovascular graft infection
  11. An uncorrectable coagulopathy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Ascending Aortic Arm

    Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the ascending aorta.

    Device: Endovascular stent-graft implantation

  • Experimental
    Arch Branch Arm

    Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the aortic arch.

    Device: Endovascular stent-graft implantation

  • Experimental
    Thoracoabdominal Aortic Arm

    Investigational endovascular stent-graft implantation to exclude thoracoabdominal aortic pathology including aortic aneurysms, renal artery aneurysms, and superior mesenteric artery aneurysms.

    Device: Endovascular stent-graft implantation

Interventions

  • DeviceEndovascular stent-graft implantation

    Endovascular repair of aorta: Patient-specific F/BEVAR treatment

    Also known as: Arch Branched Device (Cook Medical), Helical Hypogastric Branched Device (Cook Medical), Ascending Aortic Endograft (Cook Medical), Patient-specific company manufactured Fenestrated/Branched Endovascular Device (Cook Medical)

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Freedom from death in perioperative and follow up time period

    Time frame: 5 years

  2. Stroke and TIA

    Freedom from peri-operative neurologic event

    Time frame: 30 days

  3. Aneurysm-related death

    Freedom from aneurysm death related to reintervention or incomplete repair

    Time frame: 5 years

07

Study locations

2 sites
08

References and documents

Publications

  • Mesnard T, Huang Y, Schanzer A, Timaran CH, Schneider DB, Mendes BC, Eagleton MJ, Farber MA, Parodi FE, Gasper WJ, Beck AW, Sweet MP, Zetterval SL, Lee A, Oderich GS; United States Aortic Research Consortium. Multicenter Prospective Evaluation of Patient Radiation Exposure During Fenestrated-branched Endovascular Aortic Repair: A Ten-year Experience. Ann Surg. 2026 Jul 1;284(1):184-193. doi: 10.1097/SLA.0000000000006676. Epub 2025 Feb 18. PubMed 39963789 ↗
  • Oderich GS, Huang Y, Harmsen WS, Tenorio ER, Schanzer A, Timaran CH, Schneider DB, Mendes BC, Eagleton MJ, Farber MA, Gasper WJ, Beck AW, Sweet MP, Lee WA; United States Aortic Research Consortium. Early and Late Aortic-Related Mortality and Rupture After Fenestrated-Branched Endovascular Aortic Repair of Thoracoabdominal Aortic Aneurysms: A Prospective Multicenter Cohort Study. Circulation. 2024 Oct 22;150(17):1343-1353. doi: 10.1161/CIRCULATIONAHA.123.068234. Epub 2024 Jul 11. PubMed 38989575 ↗
  • Finnesgard EJ, Beck AW, Eagleton MJ, Farber MA, Gasper WJ, Lee WA, Oderich GS, Schneider DB, Sweet MP, Timaran CH, Simons JP, Schanzer A; United States Aortic Research Consortium. Severity of acute kidney injury is associated with decreased survival after fenestrated and branched endovascular aortic aneurysm repair. J Vasc Surg. 2023 Oct;78(4):892-901. doi: 10.1016/j.jvs.2023.05.034. Epub 2023 Jun 16. PubMed 37330702 ↗
  • Aucoin VJ, Motyl CM, Novak Z, Eagleton MJ, Farber MA, Gasper W, Oderich GS, Mendes B, Schanzer A, Tenorio E, Timaran CH, Schneider DB, Sweet MP, Zettervall SL, Beck AW; U.S. Aortic Research Consortium. Predictors and outcomes of spinal cord injury following complex branched/fenestrated endovascular aortic repair in the US Aortic Research Consortium. J Vasc Surg. 2023 Jun;77(6):1578-1587. doi: 10.1016/j.jvs.2023.01.205. Epub 2023 Apr 13. PubMed 37059239 ↗
  • Haulon S, Greenberg RK, Spear R, Eagleton M, Abraham C, Lioupis C, Verhoeven E, Ivancev K, Kolbel T, Stanley B, Resch T, Desgranges P, Maurel B, Roeder B, Chuter T, Mastracci T. Global experience with an inner branched arch endograft. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1709-16. doi: 10.1016/j.jtcvs.2014.02.072. Epub 2014 Feb 28. PubMed 24685375 ↗
  • Brown CR, Greenberg RK, Wong S, Eagleton M, Mastracci T, Hernandez AV, Rigelsky CM, Moran R. Family history of aortic disease predicts disease patterns and progression and is a significant influence on management strategies for patients and their relatives. J Vasc Surg. 2013 Sep;58(3):573-81. doi: 10.1016/j.jvs.2013.02.239. Epub 2013 Jul 1. PubMed 23809203 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2018 (actual). Primary completion is estimated for Dec 2030, 146 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2007
First posted
Dec 31, 2007
StartActual
Oct 25, 2018
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00583817
Lead sponsor
Matthew Eagleton
Responsible party
Matthew Eagleton (Physician Sponsor/PI, Massachusetts General Hospital) — Sponsor-investigator
First posted
Dec 31, 2007
Start date
Oct 25, 2018
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

Matthew J Eagleton, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion